A phase 3, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment for advanced non-small cell lung cancer.

Trial Profile

A phase 3, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment for advanced non-small cell lung cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2015

At a glance

  • Drugs Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 13 Feb 2012 Quality-of-life results published in the Lancet Oncology.
    • 27 Sep 2011 Actual end date changed from Mar 2010 to Dec 2011 as reported by ClinicalTrials.gov.
    • 20 Sep 2009 Primary endpoint 'Progression free survival duration' has been met according to results published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top